European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
STAT5d
Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...
Worldcrunch on MSN1d
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?
Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...
France 2417h
The fight against Alzheimer’s disease: How effective and safe is lecanemab?
In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...
FiercePharma5d
EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...
Medscape4d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
GlobalData on MSN1d
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
San Francisco Examiner6d
European watchdog partially approves new Alzheimer's drug
has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild ...
STAT4d
Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
ジャパンタイムズ4d
European agency switches to recommending new Alzheimer's drug
The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval ...
ABC News6d
European committee takes a second look at Alzheimer's drug and now says it should be approved
received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease. The European Commission is now ...